Bank of America
MLTX icon

Bank of America’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bank of America’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5M Buy
724,794
+711,261
+5,256% +$11.8M ﹤0.01% 2720
2025
Q4 		$178K Buy
13,533
+9,001
+199% +$106K ﹤0.01% 5394
2025
Q3 		$32.5K Buy
4,532
+1,781
+65% +$92.8K ﹤0.01% 6956
2025
Q2 		$130K Sell
2,751
-88,423
-97% -$3.6M ﹤0.01% 6386
2025
Q1 		$3.56M Buy
91,174
+45,634
+100% +$1.97M ﹤0.01% 4158
2024
Q4 		$2.47M Sell
45,540
-76,559
-63% -$3.91M ﹤0.01% 4260
2024
Q3 		$6.16M Buy
122,099
+68,063
+126% +$3.19M ﹤0.01% 3540
2024
Q2 		$2.38M Buy
54,036
+33,177
+159% +$1.41M ﹤0.01% 4314
2024
Q1 		$1.05M Sell
20,859
-17,326
-45% -$940K ﹤0.01% 4906
2023
Q4 		$2.31M Buy
38,185
+1,832
+5% +$94.4K ﹤0.01% 4263
2023
Q3 		$2.07M Sell
36,353
-6,304
-15% -$348K ﹤0.01% 4216
2023
Q2 		$2.18M Buy
42,657
+32,377
+315% +$871K ﹤0.01% 4155
2023
Q1 		$220K Buy
10,280
+2,380
+30% +$40K ﹤0.01% 5875
2022
Q4 		$83K Buy
+7,900
New +$70.3K ﹤0.01% 6305

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America's MLTX Position: Q1 2026 in Review

Bank of America increased its MoonLake Immunotherapeutics (MLTX) stake by 5,256% in Q1 2026, buying an estimated $11.8M and bringing the position to 724,794 shares worth $13.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2720.

Bank of America first reported a position in MLTX in Q4 2022 and has held it in 14 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Bank of America held 724,794 shares of MoonLake Immunotherapeutics worth $13.5M as of Q1 2026.
  • Bank of America bought 711,261 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $11.8M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2720 holding.
  • Bank of America first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 14 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.